---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-249556"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-10-03T23:59:59+00:00"
generated_at: "2026-06-10T05:33:42.331728+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology receives $50M from BARDA for next-gen COVID-19 mAb and pandemic preparedness

## Summary
- BARDA awards $40M via Project NextGen for VIR-7229 Phase 1 trial, expected completion H2 2025.
- Additional $10M for discovery of mAbs against a second pandemic-potential pathogen.
- Vir also receives ~$11M to wind down PENINSULA trial of influenza A mAb VIR-2482.
- Existing BARDA Agreement allows up to $1B total investment; $55M already provided for VIR-2482.
- Funds support alternative mAb delivery technologies for COVID-19 and broader pandemic response.

## SEC filing metadata
- accession: 0001193125-23-249556
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312523249556/0001193125-23-249556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312523249556/d554605d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-249556
- JSON: https://secwatch.observer/filing/0001193125-23-249556.json
- Plain text: https://secwatch.observer/filing/0001193125-23-249556.txt

## Key facts
- Material Agreements
  Vir Biotechnology, Inc. amended BARDA Agreement with Biomedical Advanced Research and Development Authority (BARDA) valued at $50 million (effective 2023-09-29).
  - Action: amendment
  - Counterparty: Biomedical Advanced Research and Development Authority (BARDA)
  - Value: $50 million
  - Effective: 2023-09-29
  source text: On September 29, 2023, Vir Biotechnology, Inc. (the “Company” or “Vir”) and the Biomedical Advanced Research and Development Authority (“BARDA”), part of the U.S. Department of Health and Human Services’ (“HHS”) Administration for Strategic Preparedness and Response, entered into Amendment No. P00001 to their Other Transaction Authority Agreement (as amended, the “BARDA Agreement”) pursuant to which BARDA awarded the Company $50 million in new funding
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523249556/0001193125-23-249556-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.